Concord Wealth Partners Moderna, Inc. Transaction History
Concord Wealth Partners
- $591 Million
- Q3 2024
A detailed history of Concord Wealth Partners transactions in Moderna, Inc. stock. As of the latest transaction made, Concord Wealth Partners holds 510 shares of MRNA stock, worth $21,618. This represents 0.01% of its overall portfolio holdings.
Number of Shares
510
Previous 410
24.39%
Holding current value
$21,618
Previous $48,000
29.17%
% of portfolio
0.01%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding MRNA
# of Institutions
933Shares Held
240MCall Options Held
10.6MPut Options Held
18.7M-
Baillie Gifford & CO42.5MShares$1.8 Billion2.17% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.2MShares$1.71 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY25.6MShares$1.08 Billion0.07% of portfolio
-
State Street Corp Boston, MA16.8MShares$714 Million0.05% of portfolio
-
Theleme Partners LLP London, X07.23MShares$306 Million28.47% of portfolio
About Moderna, Inc.
- Ticker MRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 391,200,000
- Market Cap $16.6B
- Description
- Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...